Matthew Gumbleton

Matthew Gumbleton, MD, PhD

Languages spoken: English

Clinical Locations

Huntsman Cancer Institute - Cancer Research North

Clinic 2D/E, BMT/Hematology
801-585-0100

  • Specialties

    Board Certification

    American Board of Internal Medicine (Internal Medicine)
    American Board of Internal Medicine (Sub: Medical Oncology)
    National Board of Medical Examiners

  • Board Certification and Academic Information

    Academic Departments Internal Medicine -Primary
    Academic Divisions Oncology
    Board Certification
    American Board of Internal Medicine (Internal Medicine)
    American Board of Internal Medicine (Sub: Medical Oncology)
    National Board of Medical Examiners

    Education history

    Postdoctoral Fellowship Huntsman Cancer Institute Postdoctoral Research Fellow
    Hematology & Medical Oncology - Huntsman Cancer Institute Fellow
    Residency Internal Medicine - University of Utah School of Medicine Resident
    Internal Medicine - University of Utah School of Medicine Intern/Resident
    Professional Medical Microbiology & Immunology - SUNY Upstate Medical University Norton College of Medicine M.D., Ph.D.
    Microbiology & Immunology - Kalamazoo College B.S.

    Selected Publications

    Journal Article

    1. Gumbleton M, Allan S, Conway H, Boucher K, Marvin J, Hawks J, Burnett W, Van Brocklin M, Whisenant J, Gilcrease G, Gupta S (2023). A phase I open-label study of the safety and efficacy of apatinib (rivoceranib) administered to patients with advanced malignancies to improve sensitivity to pembrolizumab in the second- or later-line setting (APPEASE). BMC Res Notes, 16(1), 16.
    2. Gumbleton M, Sudan R, Fernandes S, Engelman RW, Russo CM, Chisholm JD, Kerr WG (2017). Dual enhancement of T and NK cell function by pulsatile inhibition of SHIP1 improves antitumor immunity and survival. Sci Signal, 10(500).
    3. Iyer S, Brooks R, Gumbleton M, Kerr WG (2015). SHIP1-expressing mesenchymal stem cells regulate hematopoietic stem cell homeostasis and lineage commitment during aging. Stem Cells Dev, 24(9), 1073-81.
    4. Gumbleton M, Vivier E, Kerr WG (2015). SHIP1 intrinsically regulates NK cell signaling and education, resulting in tolerance of an MHC class I-mismatched bone marrow graft in mice. J Immunol, 194(6), 2847-54.
    5. Fernandes S, Brooks R, Gumbleton M, Park MY, Russo CM, Howard KT, Chisholm JD, Kerr WG (2015). SHIPi Enhances Autologous and Allogeneic Hematolymphoid Stem Cell Transplantation. EBioMedicine, 2(3), 205-213.
    6. Gumbleton M, Kerr WG (2013). Role of inositol phospholipid signaling in natural killer cell biology. Front Immunol, 4, 47.
    7. Fuhler GM, Brooks R, Toms B, Iyer S, Gengo EA, Park MY, Gumbleton M, Viernes DR, Chisholm JD, Kerr WG (2012). Therapeutic potential of SH2 domain-containing inositol-5'-phosphatase 1 (SHIP1) and SHIP2 inhibition in cancer. Mol Med, 18(1), 65-75.
    8. Puel A, Cypowyj S, Bustamante J, Wright JF, Liu L, Lim HK, Migaud M, Israel L, Chrabieh M, Audry M, Gumbleton M, Toulon A, Bodemer C, El-Baghdadi J, Whitters M, Paradis T, Brooks J, Collins M, Wolfman NM, Al-Muhsen S, Galicchio M, Abel L, Picard C, Casanova JL (2011). Chronic mucocutaneous candidiasis in humans with inborn errors of interleukin-17 immunity. Science, 332(6025), 65-8.

    Patent

    1. William K, Gumbleton M (2020). Ship inhibition to induce activation of natural killer cells. U.S. Patent No. WO2015195812. Washington, D.C.:U.S. Patent and Trademark Office.